Despite reaching new heights in breast cancer, Eli Lilly’s Verzenio has been sent packing in prostate cancer.  Verzenio failed to significantly prolong the t...

Even with Leqembi now sporting a full FDA approval and benefiting from the simpler Medicare coverage that distinction brings, Eisai and Biogen’s latest Alzheimer’s d...

After Amgen completed its $27.8 billion buyout of Horizon Therapeutics in October, executives at the California biotech made it a priority to right the course of thy...

With the previous year in the rearview and exciting developments already in the mix for 2024, Novo Nordisk’s CEO is taking home a cool 13% raise for his performance ...

AstraZeneca-partnered Enhertu has become a bright spot in Daiichi Sankyo’s business, and the Japanese pharma has again increased its sales projection for the HER2-di...

More than two years after Aduhelm's controversial and ill-fated FDA accelerated approval, Biogen is discontinuing the Alzheimer's disease therapy after walking a roc...

After charting a series of sales increases in 2023, Teva’s largely made good on the promise of its new CEO’s “Pivot to Growth” campaign. With group revenues on the u...

Teva’s transformation under new CEO Richard Francis is taking another turn. Wednesday, the company confirmed plans to sell its active pharmaceutical ingredients b...

Dangerously low levels of blood sugar—attributed to counterfeit versions of Novo Nordisk’s Ozempic—hospitalized three people in the United States last year, the Amer...

Over the years, myriad generic drugmakers have had to ante up fines and settlement fees for allegedly colluding on the prices of copycat drugs. Now, Apotex and two o...